country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Referencia número: HY-171124

Copy Link Print Information

Tilatamig samrotecan

Name: Tilatamig samrotecan
Brand: MedChemExpress
SKU: HY-171124
Price: 1100.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: AZD9592)

Revisión del cliente

Based on 1 Customer Validation

Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 95.26%
Peso molecular:151659 (average)

Almacenamiento:

-80°C, protect from light

Tilatamig samrotecan Chemical Structure

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vivo
- Ensayo clínico
Chemical Information
Pureza y Documentación
Referencias
Calculators
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

Topoisomerase I

Ver todos los productos específicos de isoformas EGFR :

Ver todos los productos específicos de isoformas Topoisomerase :

Ver todos los productos específicos de isoformas DNA/RNA Synthesis :

In Vivo

Tilatamig samrotecan induces a dose-dependent increase in the expression of DNA damage markers γH2AX and phosphorylated RAD-50 (pRAD50), elevates levels of cleaved caspase-3 (CC3) and reduces tumor volume (TV), in NSCLC-derived xenograft models^[1].
Tilatamig samrotecan (8 mg/kg, once) achieves tumor growth inhibition (TGI) in 73% (16/22) of models, with tumor volume reduction ≥30% from baseline in EGFR-mutant non-small cell lung cancer (NSCLC) models (heterogeneous EGFR and c-MET expression levels, and regardless of prior EGFR tyrosine kinase inhibitor treatment)^[1].
Tilatamig samrotecan (8 mg/kg, once) shows TGI in 60% (12/20) and 44% (4/9) of models in PDX models of EGFR wild-type NSCLC and head and neck squamous cell carcinoma (HNSCC), respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Liquid
Peso molecular 151659 (average)
Color Colorless to light yellow
SMILES

[Tilatamig samrotecan]
Synonyms

AZD9592
Envío

Shipping with dry ice.
Almacenamiento

-80°C, protect from light

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (269 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Lara McGrath, et al. Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Cancer research. (2023) 83 (7_Supplement): 5737.

[2]. Kinsley Wang, et al. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Antibodies (Basel). 2024 Oct 18;13(4):88. [Content Brief]

[3]. Frank Comer; et al. Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. Cancer Res (2023) 83 (7_Supplement): 5736.

Calculators

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Obtener un presupuesto En stock

Other size

Obtener un presupuesto